Eva Byröd has been selected as a new member of the Board at Nanologica.
“Eva will have an important role in Nanologica’s further development. Her solid experience within the different phases of drug development will be of great value to Nanologica’s efforts in this area,” said Gisela Sitbon, Head of the Board.
Eva Byröd has recently held the position as Project Director, Pharmaceutical Development at AstraZeneca and before that she has had several senior positions within drug development at AstraZeneca. She is replacing Mårten Steen who has declined re-election.